{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T18:51:01Z","timestamp":1791571861210,"version":"4.3.4"},"reference-count":29,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","license":[{"start":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T00:00:00Z","timestamp":1772755200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,3,6]]},"abstract":"<jats:p>\n                    Understanding the duration of the humoral immune response after coronavirus disease 2019 infection is critical for assessing vaccination strategies. This study aimed to evaluate the persistence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies in patients from Northern Jordan 1 year after infection. A descriptive cross-sectional study was conducted at King Abdullah University Hospital in Irbid, Jordan, from January to March 2021. Participants who were infected with the early SARS-CoV-2 variants circulating in Jordan (B.1, B.1.1, and B.1.1.312) prior to the emergence of the Alpha variant and unvaccinated were tested for antibodies against recombinant spike (S) and nucleocapsid (N) proteins using the quantitative Elecsys Anti-SARS-CoV-2 S and the qualitative Elecsys Anti-SARS-CoV-2 assays, respectively (Roche Diagnostics GmbH, Mannheim). Data were analyzed using Statistical Package for Social Sciences, and chi-square tests were applied to identify associations. Among 122 participants (62 males, 60 females), more than 50% of the patients retained detectable antibodies 1 year postinfection. Spike protein antibodies showed a more consistent long-term presence compared to nucleocapsid antibodies. Blood group O individuals showed the lowest seropositivity rates (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005=\u2005.06). Other variables, including age, gender, comorbidities, smoking status, and symptom severity, did not show a significant correlation with antibody persistence. SARS-CoV-2 antibodies persist in more than 50% of patients for at least 1 year postinfection, particularly against the spike protein. These findings support the potential for long-term immune protection and may inform vaccination policies, particularly in resource-limited settings.\n                  <\/jats:p>","DOI":"10.1097\/md.0000000000047902","type":"journal-article","created":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T08:01:36Z","timestamp":1773043296000},"page":"e47902","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["One-year seropositivity after COVID-19 infection: A study from a developing country"],"prefix":"10.1097","volume":"105","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5541-8362","authenticated-orcid":false,"given":"Nasr","family":"Alrabadi","sequence":"first","affiliation":[{"name":"Department of Pharmacology, Faculty of Medicine, Jordan University of Science and Technology, Irbid, Jordan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haneen","family":"Obeidat","sequence":"additional","affiliation":[{"name":"Department of Medical Laboratory Sciences, Faculty of Applied Medical Sciences, Jordan University of Science and Technology, Irbid, Jordan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Razan","family":"Haddad","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, Faculty of Pharmacy, Jadara University, Irbid, Jordan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osama","family":"Alzoubi","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Medicine, University of Illinois at Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daher","family":"Al-rabadi","sequence":"additional","affiliation":[{"name":"Department of Community and Mental Health Nursing, Faculty of Nursing, Jordan University of Science and Technology, Irbid, Jordan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saied","family":"Jaradat","sequence":"additional","affiliation":[{"name":"Princess Haya Biotechnology Center, Jordan University of Science and Technology, Irbid, Jordan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam K.","family":"El-zubi","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, College of Pharmacy, Gulf Medical University, Ajman, United Arab Emirates"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rania","family":"Harati","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice and Pharmacotherapeutics, University of Sharjah, Sharjah, United Arab Emirates"},{"name":"Research Institute for Medical and Health Sciences, University of Sharjah, Sharjah, United Arab Emirates"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2808-5099","authenticated-orcid":false,"given":"Karem H.","family":"Alzoubi","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice and Pharmacotherapeutics, College of Pharmacy, University of Sharjah, Sharjah, United Arab Emirates"},{"name":"Department of Clinical Pharmacy, Faculty of Pharmacy, Jordan University of Science and Technology, Irbid, Jordan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibrahim","family":"Al-faouri","sequence":"additional","affiliation":[{"name":"Department of Community and Mental Health Nursing, Faculty of Nursing, Jordan University of Science and Technology, Irbid, Jordan"},{"name":"College of Nursing, RAK Medical and Health Sciences University, Ras Al Khaimah, United Arab Emirates."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20261009","doi-asserted-by":"crossref","first-page":"3633","DOI":"10.1111\/febs.15375","article-title":"A guide to COVID\u201019: a global pandemic caused by the novel coronavirus SARS\u2010CoV\u20102.","volume":"287","author":"Atzrodt","year":"2020","journal-title":"FEBS J"},{"key":"R2-20261009","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/S2213-2600(20)30514-2","article-title":"COVID-19 transmission\u2014up in the air.","volume":"8","year":"2020","journal-title":"Lancet Respir Med"},{"key":"R3-20261009","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.cca.2020.05.044","article-title":"COVID-19: transmission, prevention, and potential therapeutic opportunities.","volume":"508","author":"Lotfi","year":"2020","journal-title":"Clin Chim Acta"},{"key":"R4-20261009","doi-asserted-by":"crossref","first-page":"101623","DOI":"10.1016\/j.tmaid.2020.101623","article-title":"Clinical, laboratory and imaging features of COVID-19: a systematic review and meta-analysis.","volume":"34","author":"Rodriguez-Morales","year":"2020","journal-title":"Travel Med Infect Dis"},{"key":"R5-20261009","first-page":"CD013665","article-title":"Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19 disease.","volume":"7","author":"Struyf","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"R6-20261009","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1177\/01410768211032850","article-title":"Symptoms, complications and management of long COVID: a review.","volume":"114","author":"Aiyegbusi","year":"2021","journal-title":"J R Soc Med"},{"key":"R8-20261009","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/S0140-6736(20)30567-5","article-title":"How will country-based mitigation measures influence the course of the COVID-19 epidemic?","volume":"395","author":"Anderson","year":"2020","journal-title":"Lancet"},{"key":"R9-20261009","doi-asserted-by":"crossref","first-page":"m1924","DOI":"10.1136\/bmj.m1924","article-title":"Should governments continue lockdown to slow the spread of covid-19?","volume":"369","author":"Melnick","year":"2020","journal-title":"BMJ"},{"key":"R10-20261009","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1186\/s12889-022-14177-7","article-title":"On the effectiveness of COVID-19 restrictions and lockdowns: pan metron ariston.","volume":"22","author":"Spiliopoulos","year":"2022","journal-title":"BMC Public Health"},{"key":"R11-20261009","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1111\/joms.12644","article-title":"\u201815 days to slow the spread\u2019: Covid\u201019 and collective resilience.","volume":"58","author":"Glynn","year":"2021","journal-title":"J Manag Stud"},{"key":"R12-20261009","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1111\/bjso.12487","article-title":"Together we can slow the spread of COVID\u201019: the interactive effects of priming collectivism and mortality salience on virus\u2010related health behaviour intentions.","volume":"61","author":"Courtney","year":"2022","journal-title":"Br J Soc Psychol"},{"key":"R13-20261009","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1002\/jmv.27420","article-title":"Evaluation of antibody response after COVID\u201019 vaccination of healthcare workers.","volume":"94","author":"Uysal","year":"2022","journal-title":"J Med Virol"},{"key":"R14-20261009","doi-asserted-by":"crossref","first-page":"3501","DOI":"10.1007\/s00216-021-03298-4","article-title":"Spike vs nucleocapsid SARS-CoV-2 antigen detection: application in nasopharyngeal swab specimens.","volume":"413","author":"Barlev-Gross","year":"2021","journal-title":"Anal Bioanal Chem"},{"key":"R15-20261009","doi-asserted-by":"crossref","first-page":"115659","DOI":"10.1016\/j.diagmicrobio.2022.115659","article-title":"Lower persistence of anti-nucleocapsid compared to anti-spike antibodies up to one year after SARS-CoV-2 infection.","volume":"103","author":"Van Elslande","year":"2022","journal-title":"Diagn Microbiol Infect Dis"},{"key":"R16-20261009","doi-asserted-by":"crossref","first-page":"634022","DOI":"10.3389\/fpubh.2020.634022","article-title":"The battle against COVID-19 in Jordan: from extreme victory to extreme burden.","volume":"8","author":"Khatatbeh","year":"2021","journal-title":"Front Public Health"},{"key":"R17-20261009","doi-asserted-by":"crossref","first-page":"4144","DOI":"10.1038\/s41467-021-24230-5","article-title":"Twelve-month specific IgG response to SARS-CoV-2 receptor-binding domain among COVID-19 convalescent plasma donors in Wuhan.","volume":"12","author":"Li","year":"2021","journal-title":"Nat Commun"},{"key":"R18-20261009","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1093\/infdis\/jiab255","article-title":"Persistence of antibody and cellular immune responses in coronavirus disease 2019 patients over nine months after infection.","volume":"224","author":"Yao","year":"2021","journal-title":"J Infect Dis"},{"key":"R19-20261009","doi-asserted-by":"crossref","first-page":"e01828","DOI":"10.1128\/JVI.01828-20","article-title":"Changes in SARS-CoV-2 spike versus nucleoprotein antibody responses impact the estimates of infections in population-based seroprevalence studies.","volume":"95","author":"Fenwick","year":"2021","journal-title":"J Virol"},{"key":"R20-20261009","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1038\/s41564-020-00813-8","article-title":"Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans.","volume":"5","author":"Seow","year":"2020","journal-title":"Nat Microbiol"},{"key":"R21-20261009","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1126\/science.abd7728","article-title":"Robust neutralizing antibodies to SARS-CoV-2 infection persist for months.","volume":"370","author":"Wajnberg","year":"2020","journal-title":"Science"},{"key":"R22-20261009","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1038\/s41586-021-03207-w","article-title":"Evolution of antibody immunity to SARS-CoV-2.","volume":"591","author":"Gaebler","year":"2021","journal-title":"Nature"},{"key":"R23-20261009","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1111\/vox.13070","article-title":"ABO blood group and SARS\u2010CoV\u20102 antibody response in a convalescent donor population.","volume":"116","author":"Bloch","year":"2021","journal-title":"Vox Sang"},{"key":"R24-20261009","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1111\/trf.16524","article-title":"Blood group O convalescent plasma donations have significantly lower levels of SARS\u2010CoV-2 IgG antibodies compared to blood group A donations.","volume":"61","author":"Hayes","year":"2021","journal-title":"Transfusion"},{"key":"R25-20261009","doi-asserted-by":"crossref","first-page":"385","DOI":"10.31083\/j.rcm.2020.03.78","article-title":"SARS-CoV-2 infection in patients with diabetes mellitus and hypertension: a systematic review.","volume":"21","author":"Deravi","year":"2020","journal-title":"Rev Cardiovasc Med"},{"key":"R26-20261009","doi-asserted-by":"crossref","first-page":"e214302","DOI":"10.1001\/jamanetworkopen.2021.4302","article-title":"Association of age with SARS-CoV-2 antibody response.","volume":"4","author":"Yang","year":"2021","journal-title":"JAMA Netw Open"},{"key":"R27-20261009","article-title":"Immune system and COVID-19 by sex differences and age.","volume":"17","author":"Ciarambino","year":"2021","journal-title":"Women\u2019s Health"},{"key":"R28-20261009","doi-asserted-by":"crossref","first-page":"e146242","DOI":"10.1172\/jci.insight.146242","article-title":"Comorbid illnesses are associated with altered adaptive immune responses to SARS-CoV-2.","volume":"6","author":"Yu","year":"2021","journal-title":"JCI Insight"},{"key":"R29-20261009","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.puhe.2021.12.013","article-title":"Does smoking have an impact on the immunological response to COVID-19 vaccines? Evidence from the VASCO study and need for further studies.","volume":"203","author":"Ferrara","year":"2022","journal-title":"Public Health"},{"key":"R30-20261009","doi-asserted-by":"crossref","first-page":"e0253977","DOI":"10.1371\/journal.pone.0253977","article-title":"Characterization of antibody response in asymptomatic and symptomatic SARS-CoV-2 infection.","volume":"16","author":"Marchi","year":"2021","journal-title":"PLoS One"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000047902","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T18:08:53Z","timestamp":1791569333000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000047902"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,6]]},"references-count":29,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000047902","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,6]]},"assertion":[{"value":"2025-06-15","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-11","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}